In a study analyzing patients on SGLT2i monotherapy or in combination with other antidiabetics (including metformin, SU, meglitinide, DPP-4i, TZD, α-glucosidase inhibitors, or insulin), SGLT2i use was associated with reduced risk of both AD and all-cause dementia when compared with participants on oral antidiabetic drugs other than SGLT2i, with or without insulin, for over 90 days [390]. The gene discussed is INS; the disease is dementia.